Loading...
XSTOPLUN
Market cap2mUSD
Dec 23, Last price  
9.00SEK
1D
-0.44%
1Q
2,155.64%
Jan 2017
24.82%
IPO
-13.60%
Name

ProstaLund AB

Chart & Performance

D1W1MN
XSTO:PLUN chart
P/E
—
P/S
1.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.08%
Rev. gr., 5y
10.36%
Revenues
22m
+27.54%
7,654,0008,614,0009,613,00013,613,00014,612,00013,544,00013,567,00012,886,00012,465,00017,073,00017,411,00022,206,000
Net income
-17m
L+50.49%
-561,000-4,645,000-7,786,000-9,373,000-11,974,000-16,894,000-12,950,000-10,728,000-10,041,000-7,919,000-11,303,000-17,010,000
CFO
-24m
L+46.90%
-2,605,000-3,875,000-10,834,000-9,750,000-14,407,000-16,114,000-11,893,000-9,115,000-8,581,000-5,804,000-16,202,000-23,801,000

Profile

ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.
URL
https://www.prostalund.se/
IPO date
Oct 24, 2013
Employees
10
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
22,206
27.54%
17,411
1.98%
17,073
36.97%
Cost of revenue
38,778
28,339
24,660
Unusual Expense (Income)
NOPBT
(16,572)
(10,928)
(7,587)
NOPBT Margin
Operating Taxes
205
35
Tax Rate
NOPAT
(16,572)
(11,133)
(7,622)
Net income
(17,010)
50.49%
(11,303)
42.73%
(7,919)
-21.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
33,942
19,837
18,737
BB yield
-30.42%
-9.11%
-9.44%
Debt
Debt current
400
400
200
Long-term debt
933
1,333
Deferred revenue
Other long-term liabilities
(1,333)
Net debt
(14,017)
(10,542)
(13,039)
Cash flow
Cash from operating activities
(23,801)
(16,202)
(5,804)
CAPEX
(146)
(4,754)
(9,187)
Cash from investing activities
(3,345)
(4,754)
(9,187)
Cash from financing activities
30,221
19,992
17,735
FCF
(25,020)
(13,925)
(5,797)
Balance
Cash
15,350
12,275
13,239
Long term investments
Excess cash
14,240
11,404
12,385
Stockholders' equity
(114,221)
(51,635)
(41,110)
Invested Capital
170,845
95,029
76,726
ROIC
ROCE
EV
Common stock shares outstanding
68,447
54,486
47,963
Price
1.63
-59.20%
4.00
-3.50%
4.14
55.06%
Market cap
111,568
-48.74%
217,670
9.62%
198,567
94.50%
EV
97,551
311,992
278,163
EBITDA
(16,307)
(10,707)
(7,280)
EV/EBITDA
Interest
173
207
35
Interest/NOPBT